Previous Close | 3.9200 |
Open | 3.8700 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 800 |
Day's Range | 3.8601 - 4.0500 |
52 Week Range | 2.9000 - 12.3000 |
Volume | 69,687 |
Avg. Volume | 1,995,024 |
Market Cap | 40.446M |
Beta (5Y Monthly) | -1.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Mar 30, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.88 |
INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the execution of a partnership agreement with Lyfe Medical, LLC ("Lyfe Medical") focused on the expansion of the INVOcell solution in Northern California (with an area population of ~8 million people).
INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, announced today that Steve Shum, CEO of INVO Bioscience, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Democratizing Infertility - A Severely Underserved Global Market." The Event is scheduled to begin at 8:30 am Pacific/11:30 am Eastern on Tuesday, April 13, 2021.
INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results for the year ended December 31, 2020.